These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
283 related items for PubMed ID: 24910709
21. Identification of Host Factors for Rift Valley Fever Phlebovirus. Balaraman V, Indran SV, Li Y, Meekins DA, Jakkula LUMR, Liu H, Hays MP, Souza-Neto JA, Gaudreault NN, Hardwidge PR, Wilson WC, Weber F, Richt JA. Viruses; 2023 Nov 13; 15(11):. PubMed ID: 38005928 [Abstract] [Full Text] [Related]
22. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Ikegami T. Expert Rev Vaccines; 2017 Jun 13; 16(6):601-611. PubMed ID: 28425834 [Abstract] [Full Text] [Related]
23. MP-12 virus containing the clone 13 deletion in the NSs gene prevents lethal disease when administered after Rift Valley fever virus infection in hamsters. Gowen BB, Westover JB, Sefing EJ, Bailey KW, Nishiyama S, Wandersee L, Scharton D, Jung KH, Ikegami T. Front Microbiol; 2015 Jun 13; 6():651. PubMed ID: 26175722 [Abstract] [Full Text] [Related]
24. The dominant-negative inhibition of double-stranded RNA-dependent protein kinase PKR increases the efficacy of Rift Valley fever virus MP-12 vaccine. Lihoradova O, Kalveram B, Indran SV, Lokugamage N, Juelich TL, Hill TE, Tseng CT, Gong B, Fukushi S, Morikawa S, Freiberg AN, Ikegami T. J Virol; 2012 Jul 13; 86(14):7650-61. PubMed ID: 22573861 [Abstract] [Full Text] [Related]
25. Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal Rift Valley fever virus challenge. Gowen BB, Bailey KW, Scharton D, Vest Z, Westover JB, Skirpstunas R, Ikegami T. Antiviral Res; 2013 May 13; 98(2):135-43. PubMed ID: 23523764 [Abstract] [Full Text] [Related]
26. A geographical information system-based multicriteria evaluation to map areas at risk for Rift Valley fever vector-borne transmission in Italy. Tran A, Ippoliti C, Balenghien T, Conte A, Gely M, Calistri P, Goffredo M, Baldet T, Chevalier V. Transbound Emerg Dis; 2013 Nov 13; 60 Suppl 2():14-23. PubMed ID: 24589097 [Abstract] [Full Text] [Related]
27. Single-cycle replicable Rift Valley fever virus mutants as safe vaccine candidates. Terasaki K, Tercero BR, Makino S. Virus Res; 2016 May 02; 216():55-65. PubMed ID: 26022573 [Abstract] [Full Text] [Related]
28. Efficacy of a recombinant Rift Valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep. Weingartl HM, Nfon CK, Zhang S, Marszal P, Wilson WC, Morrill JC, Bettinger GE, Peters CJ. Vaccine; 2014 Apr 25; 32(20):2345-9. PubMed ID: 24462482 [Abstract] [Full Text] [Related]
29. Rift Valley fever virus NSs protein functions and the similarity to other bunyavirus NSs proteins. Ly HJ, Ikegami T. Virol J; 2016 Jul 02; 13():118. PubMed ID: 27368371 [Abstract] [Full Text] [Related]
30. Rescue of infectious Arumowot virus from cloned cDNA: Posttranslational degradation of Arumowot virus NSs protein in human cells. Hallam HJ, Lokugamage N, Ikegami T. PLoS Negl Trop Dis; 2019 Nov 02; 13(11):e0007904. PubMed ID: 31751340 [Abstract] [Full Text] [Related]
31. Rift valley fever virus nonstructural protein NSs promotes viral RNA replication and transcription in a minigenome system. Ikegami T, Peters CJ, Makino S. J Virol; 2005 May 02; 79(9):5606-15. PubMed ID: 15827175 [Abstract] [Full Text] [Related]
32. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. Bird BH, Albariño CG, Hartman AL, Erickson BR, Ksiazek TG, Nichol ST. J Virol; 2008 Mar 02; 82(6):2681-91. PubMed ID: 18199647 [Abstract] [Full Text] [Related]
33. [Rift Valley fever virus]. Ikegami T, Makino S. Uirusu; 2004 Dec 02; 54(2):229-35. PubMed ID: 15745161 [Abstract] [Full Text] [Related]
34. Novel approaches to develop Rift Valley fever vaccines. Indran SV, Ikegami T. Front Cell Infect Microbiol; 2012 Dec 02; 2():131. PubMed ID: 23112960 [Abstract] [Full Text] [Related]
35. A single-cycle replicable Rift Valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice. Terasaki K, Juelich TL, Smith JK, Kalveram B, Perez DD, Freiberg AN, Makino S. Sci Rep; 2018 Nov 20; 8(1):17097. PubMed ID: 30459418 [Abstract] [Full Text] [Related]
36. Rift Valley Fever Virus Non-Structural Protein S Is Associated with Nuclear Translocation of Active Caspase-3 and Inclusion Body Formation. Michaely LM, Rissmann M, Armando F, von Arnim F, Keller M, Eiden M, König R, Gutjahr B, Baumgärtner W, Groschup MH, Ulrich R. Viruses; 2022 Nov 10; 14(11):. PubMed ID: 36366585 [Abstract] [Full Text] [Related]
37. Candidate vaccines for human Rift Valley fever. Ikegami T. Expert Opin Biol Ther; 2019 Dec 10; 19(12):1333-1342. PubMed ID: 31478397 [Abstract] [Full Text] [Related]
38. Presence of Viral RNA and Proteins in Exosomes from Cellular Clones Resistant to Rift Valley Fever Virus Infection. Ahsan NA, Sampey GC, Lepene B, Akpamagbo Y, Barclay RA, Iordanskiy S, Hakami RM, Kashanchi F. Front Microbiol; 2016 Dec 10; 7():139. PubMed ID: 26904012 [Abstract] [Full Text] [Related]
39. Rift valley Fever in Kruger national park: do buffalo play a role in the inter-epidemic circulation of virus? Beechler BR, Bengis R, Swanepoel R, Paweska JT, Kemp A, van Vuren PJ, Joubert J, Ezenwa VO, Jolles AE. Transbound Emerg Dis; 2015 Feb 10; 62(1):24-32. PubMed ID: 24330522 [Abstract] [Full Text] [Related]